Clinical Trial Update: Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy duration and toxicity of Rituximab–Fludarabine–Cyclophosphamide as first-line therapy and Rituximab as maintenance in foll…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Cytoxan (cyclophosphamide)
• Fludara (fludarabine)
• Rituxan (rituximab)

Snippet

Sponsor: Asociacion Espanola de Hematologia y Hemoterapia | Conditions: Non Hodgkin Lymphoma | Phase 4 | Status: COMPLETED